Source: International Congress 2015 – Pulmonary hypertension: management
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Duncan Grady (Cambridge, United Kingdom), Duncan Grady, Marjorie Weiss, Joanna Pepke-Zaba. Adherence to pulmonary arterial hypertension targeted therapies. Eur Respir J 2015; 46: Suppl. 59, 3786

Member's Comments

No comment yet.

Related content which might interest you: Withdrawal of long-term epoprostenol therapy in pulmonary arterial hypertension (PAH) Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 Pulmonary arterial hypertension: treatment options Source: International Congress 2018 – ME10 Pulmonary arterial hypertension: treatment options FULLY BOOKED Year: 2018 Pulmonary Function and response to treatment in pulmonary arterial hypertension (PAH) Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016 Pulmonary arterial hypertension associated to HIV. Our experience Source: International Congress 2015 – Pulmonary hypertension: rare and hereditary causes of PAH Year: 2015 Initial dual oral combination therapy for pulmonary arterial hypertension (PAH) in daily practice Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 Heart rate recovery in response to disease targeted therapy in pre-capillary pulmonary hypertension Source: International Congress 2016 – Pulmonary hypertension: exercise, haemodynamics, and physiology Year: 2016 Pulmonary arterial hypertension in patients treated with interferon Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment Year: 2013 Beta-blocker therapy nor hyperoxic breathing lowers ventilatory drive in pulmonary arterial hypertension patients Source: International Congress 2014 – Pulmonary hypertension: right ventricular function, exercise and gas exchange Year: 2014 Long-term safety of a new formulation of epoprostenol in pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013 Specific pulmonary arterial hypertension therapy in COPD patients with severe pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 LATE-BREAKING ABSTRACT: Peak oxygen consumption improves in inoperable, but not operable, chronic thromboembolic pulmonary hypertension after treatment with pulmonary arterial hypertension drugs Source: Annual Congress 2013 –New physiologic boundaries Year: 2013 PAH-specific therapies improve survival in patients with pulmonary arterial hypertension associated with connective tissue diseases: A Russian single centre experience Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Acute haemodynamic effects of adaptive servoventilation therapy in patients with pulmonary arterial hypertension and patients with chronic thromboembolic pulmonary hypertension Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 Sildenafil improves heart rate variability, pulmonary hemodynamics and functional status in pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology Year: 2014 The effects of beta-blocker therapy on systolic and diastolic function in pulmonary arterial hypertension: A randomized controlled trial Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH Year: 2014 The effects of beta-blocker therapy on heart rate, symptoms and exercise in pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Pulmonary vascular reactivity in pulmonary hypertension due to left heart disease Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension I Year: 2013 Treatment of pulmonary hypertension Source: Virtual Congress 2020 – Treatment in pulmonary hypertension Year: 2020